Can gut-derived endotoxemia and inflammatory cytokines drive hepatic insulin resistance and MASLD progression?

The relationship between gut barrier integrity and liver health, commonly termed the gut-liver axis, is a critical factor in metabolic regulation. Substantial evidence confirms that the translocation of gut-derived inflammatory mediators directly promotes the development and progression of metabolic-associated steatotic liver disease (MASLD).

Clinical and effectiveness evidence

Large-scale longitudinal studies (with sample sizes exceeding 1,000 participants) and cross-sectional data show that chronic low-grade endotoxemia is a robust predictor of impaired hepatic glucose metabolism and metabolic syndrome. In patients with MASLD, elevated systemic levels of lipopolysaccharide (LPS) and pro-inflammatory markers—specifically high-sensitivity C-reactive protein (hs-CRP), Tumor Necrosis Factor-alpha (TNF-α), and Interleukin-6 (IL-6)—strongly correlate with increased HOMA-IR scores and steatosis severity. Furthermore, randomized controlled trials investigating gut-targeted therapies have demonstrated that improving intestinal barrier function can result in modest but statistically significant improvements in liver health, including reductions in alanine aminotransferase (ALT) levels by 5–15 U/L.

Mechanistic explanations

The transition from gut dysbiosis to liver dysfunction occurs through a well-defined molecular cascade involving both immune and metabolic signaling:

• TLR4 Activation: When the gut barrier is compromised ("leaky gut"), LPS enters the portal circulation and binds to Toll-like receptor 4 (TLR4) on hepatic Kupffer cells and hepatocytes.
• Inflammatory Signaling: This binding activates the NF-κB and JNK pathways, triggering the release of pro-inflammatory cytokines like TNF-α and IL-6.
• Insulin Signaling Interference: Elevated JNK activity and cytokines promote the inhibitory serine phosphorylation of Insulin Receptor Substrate-1 (IRS-1).
• Metabolic Disruption: This phosphorylation blocks the downstream PI3K/Akt signaling pathway. This prevents insulin from effectively suppressing hepatic gluconeogenesis and leads to unregulated lipogenesis, hallmarks of hepatic insulin resistance and MASLD.

Bottom line

• Gut-derived endotoxemia and the resulting cytokine cascade are scientifically supported drivers of MASLD physiology, operating through established TLR4-mediated pathways that directly impair insulin receptor signaling and promote hepatic lipid accumulation.